the news highlighted another factor in the chinese threat: regardless of the different regulatory framework, many researchers think the data they report is valid.
.
.
following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv).
.